论文部分内容阅读
Suvorexant(1),化学名为5-氯-2-[(5R)-5-甲基-4-[5-甲基-2-(2H-1,2,3-三唑-2-基)苯甲酰基]-1,4-二氮杂环庚烷-1-基]-1,3-苯并噁唑,是默沙东制药公司开发的用于治疗成人失眠的药物,2014年8月获美国FDA批准上市,商品名为Belsomra,剂型为片剂,有5、10、15和20 mg 4
Suvorexant (1), chemically named 5-chloro-2 - [(5R) -5- methyl- Benzoyl] -1,4-diazepan-1-yl] -1,3-benzoxazole is a drug developed by Merck & amp; East Pharmaceutical Company for the treatment of adult insomnia and was approved by the United States The FDA is marketed under the trade name Belsomra in the form of tablets with 5, 10, 15 and 20 mg 4